New investors in a little-known cancer treatment for dogs say they are “getting to grips” with the true potential of the drug.
CV247, which has been helping treat cancer in dogs since 1996, albeit on a tiny scale, is receiving ongoing investment which will help develop it further and make it far more widely available.
CV247 is produced by CV Pharma Limited, formerly Ivy Medical Chemicals Plc, and is a relatively simple drug applied as an alternative or complementary cancer treatment – with few known side-effects – used either in isolation or alongside established treatments such as chemotherapy or radiotherapy.
“Our investment due diligence and product relaunch plans revealed that CV247 is helping to treat cancer in dogs with varying levels of impact depending upon the type and the stage of the cancer, and the effectiveness of the CV247 treatment appears to be without doubt in many cases. The volume of sales has strong potential,” said Roger Wood, Chairman of CV Pharma, and one of the new team of investors.
“The development and distribution of CV247 had atrophied due to minimal income to reinvest because the inventor – Dr John Carter – was focussed on development rather than generating revenue for reinvestment, and he then died in 2010. It is fair to say the true potential has never been realised.
“But we are getting to grips with an understanding of that potential thanks to the input of both our own Technical Director, Dr Roger Oakes, and renowned veterinary medicine expert Professor Andor Sebesteny, formerly chief veterinary surgeon of the Ludwig Institute of Cancer Research, and consultant veterinary pathologist to the UK ‘s Imperial Cancer Research Fund.”
Dr Roger Oakes said: “CV247 boosts the immune system, and forms part of the body’s anti-oxidant defences. It also aids recovery as an adjunctive therapy for traditional cancer treatments, and may prevent or delay the re-occurrence of tumours, and in some cases demonstrates a regression of such tumours. It has at least limited and quite possibly no known adverse side-effects.”
Prof Sebesteny said: “Evidence has shown that, depending upon the stage and type of cancer, a significant number of animals, according to their owners, appeared to benefit from treatment with CV247, and it appears to have been responsible for improving the quality of life and extending life span in a number of dogs beyond that predicted.”
No Comment